Loading...
XNASTTNP
Market cap3mUSD
Dec 24, Last price  
3.50USD
1D
8.02%
1Q
-32.56%
Jan 2017
-99.98%
Name

Titan Pharmaceuticals Inc

Chart & Performance

D1W1MN
XNAS:TTNP chart
P/E
—
P/S
17.39
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
31.73%
Rev. gr., 5y
-50.04%
Revenues
184k
+206.67%
31,00089,00032,00024,00070,00079,00010,093,0004,068,0007,117,00010,481,0003,646,0001,671,00015,065,000215,0005,911,0003,611,0004,838,0001,526,00060,000184,000
Net income
-6m
L-45.28%
-26,004,000-22,462,000-15,737,000-17,647,000-25,430,000-5,886,000-6,834,000-15,203,000-15,180,0009,711,000-2,403,000-11,279,0005,135,000-14,307,000-9,023,000-16,089,000-20,728,000-8,114,000-10,177,000-5,569,000
CFO
-7m
L-13.33%
-23,912,000-22,921,000-13,500,000-15,188,000-25,340,000-5,407,000-4,657,000-14,476,0001,830,000-9,799,000-5,865,000-7,466,0006,293,000-13,038,000-8,431,000-15,445,000-17,203,000-7,899,000-8,183,000-7,092,000

Profile

Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform. The company offers Probuphine implant for the maintenance treatment of opioid use disorder in clinically stable patients in Canada and the European Union. It is also developing kappa opioid agonist peptide program (TP-2021) for use in combination with ProNeura technology for the treatment of chronic pruritus; nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder; and other programs, including HIV preventative therapeutic and a contraceptive from a single ProNeura implant for women and adolescent girls. The company was incorporated in 1992 and is based in South San Francisco, California.
URL
https://www.titanpharm.com/
IPO date
Jan 18, 1996
Employees
4
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
184
206.67%
60
-96.07%
1,526
-68.46%
Cost of revenue
9,374
10,988
10,880
Unusual Expense (Income)
NOPBT
(9,190)
(10,928)
(9,354)
NOPBT Margin
Operating Taxes
(29)
(662)
Tax Rate
NOPAT
(9,190)
(10,899)
(8,692)
Net income
(5,569)
-45.28%
(10,177)
25.43%
(8,114)
-60.85%
Dividends
Dividend yield
Proceeds from repurchase of equity
9,500
4,984
8,841
BB yield
-3,062.54%
-947.51%
-1,781.63%
Debt
Debt current
565
122
112
Long-term debt
65
252
486
Deferred revenue
Other long-term liabilities
Net debt
(6,130)
(2,563)
(5,439)
Cash flow
Cash from operating activities
(7,092)
(8,183)
(7,899)
CAPEX
(2)
(23)
Cash from investing activities
732
(23)
Cash from financing activities
10,000
4,984
8,841
FCF
(9,217)
(10,589)
(8,650)
Balance
Cash
6,760
2,937
6,037
Long term investments
Excess cash
6,751
2,934
5,961
Stockholders' equity
(391,828)
(386,246)
(376,045)
Invested Capital
399,035
387,796
381,482
ROIC
ROCE
EV
Common stock shares outstanding
752
672
486
Price
0.41
-47.32%
0.78
-23.23%
1.02
-69.00%
Market cap
310
-41.03%
526
6.00%
496
-20.05%
EV
(5,819)
(2,037)
(4,943)
EBITDA
(9,078)
(10,732)
(9,133)
EV/EBITDA
0.64
0.19
0.54
Interest
29
1,000
Interest/NOPBT